# ublic Health Link

om the Chief Medical Officer for Wales

Distribution:	A A !! O	
Distribution;	As Appendix 2	
From:	Chief Pharmaceutical Officer, Andrew Evans	
Date:	21 November 2019	
Reference:	CEM/CPhA/2019/37	
Category:	Class 2: Action With 48 Hours	
Title:	Class 2 Drug Alert, Action Within 48 Hours, Creo Pharma Limited (Zentiva Pharma Uk Ltd), Ranitidine Oral Solution 30mg/Ml And Tillomed Laboratories Limited, Ranitidine 150mg Tablets	
For Action by:		
dispensary see t Action as below.	eral Practitioners – Ensure all working in your his alert and a copy is held on your locum file – macies – Action as below	
	cies – Action as below.	
Chief Pharmacist	rs - Action as below.	
For Information:	See Annex 2 – Distribution List	
What is this about:	Full details are set out below.	
Why has it been sent:	For your information, action and to pass on to colleagues.	

#### Issue:

Creo Pharma Limited and Tillomed Laboratories Limited are recalling all unexpired stock of the above products as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website <a href="https://www.gov.uk/drug-device-alerts">https://www.gov.uk/drug-device-alerts</a>.

### **Appendix 1**

To: Chief Executives of Health Boards and NHS Trusts

To: Medical Directors of Health Boards

To: Nurse Directors Health Boards

To: Directors of Public Health

To: Hospital Principals and Chief Pharmacists to action as per alert

## To: NHS Wales Shared Services Partnership to forward to:

Dispensing General Practitioners – Ensure all working in your dispensary see this alert and a copy is held on your locum file.

**Community Pharmacies** 

Deputising services

**HB Prescribing Advisers** 

Independent/Private clinics and Hospitals and Hospices throughout Wales





## DRUG ALERT

## **CLASS 2 MEDICINES RECALL**

# Action Within 48 Hours Pharmacy/Wholesaler/Retail Store Level Recall

Date: 21 November 2019

EL (19)A/37

Our Ref: MDR 56-09/19

Dear Healthcare Professional,

## **OTC Concepts Limited**

Product	PL Number	
Ranitidine 75mg Tablets	PL 20338/0020	

## **Relonchem Limited**

Product	PL Number
Relonchem Ranitidine 75mg Tablets (6)	PL 20395/0079
Relonchem Ranitidine 75mg Tablets (12)	PL 20395/0079
Bells Healthcare Ranitidine 75mg Tablets (12)	PL 20395/0079
Numark Ranitidine 75mg Film Coated Tablets (12)	PL 20395/0079
Tesco Heartburn and Indigestion Relief 75mg Film Coated Tablets (12)	PL 20395/0079

## **Noumed Life Sciences Limited**

Product	PL Number
Noumed Indigestion Relief 75mg Film-Coated	PL 44041/0027
Tablets	
Gavilast Heartburn and Indigestion 75mg Film-	PL 44041/0028
Coated Tablets	
Ranitidine 75mg Film-Coated Tablets	PL 44041/0028

EL (19)A/37 Page 1 of 4





#### **Medreich PLC**

ASDA Ranitidine 75 mg Tablets (12)		PL 21880/0022	
Batch Number	Expiry Date	Pack Size	First Distributed
370190	31/01/2020	1 x 12	August 2017

Peach Ethical Indigestion Film Coated Tablets (12)		PL 21880/0022	
Batch Number	Expiry Date	Pack Size	First Distributed
370049	31/12/2019	1 x 12	October 2017

Sainsbury's Indigestion Relief Tablets (12)		PL 21880/0022	
Batch Number	Expiry Date	Pack Size	First Distributed
370065	31/12/2019	1 x 12	May 2017
370066	31/12/2019	1 x 12	May 2017

Tesco Indigestion Relief Ranitidine 75mg film- coated tablets		PL 21880/0022	
Batch Number	Expiry Date	Pack Size	First Distributed
370050	31/12/2019	1 x 12	March 2017
370051	31/12/2019	1 x 12	March 2017
370052	31/12/2019	1 x 12	April 2017
370064	31/12/2019	1 x 12	May 2017

Generic Name: Ranitidine

OTC Concepts Ltd, Relconchem Ltd and Noumed Life Sciences Ltd are recalling all unexpired batches of the above products from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Medreich Plc are recalling specific batches of the above products from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

## Advice for healthcare professionals and retail stores

- Stop supplying the above products immediately and remove from the shelves within your store.
   Quarantine all remaining stock and return it to your supplier using your supplier's approved process.
- If you receive queries about this issue from patients, advise them to contact their GP, pharmacist
  or healthcare professional to review ongoing treatment.

EL (19)A/37 Page 2 of 4





This is an on-going issue and the MHRA is actively involved with the European Medicines Agency and with other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

#### Company contacts for further information

#### **OTC Concepts Limited**

- For stock control enquiries please contact Customer Service team on +44 (0) 1484 665733 or Warehouse@dalkeithlabs.co.uk
- For medical information enquiries please contact Pharmacovigilance Department on +44 (0) 1525 292344 or <u>RanitidinePV@dalkeithlabs.co.uk</u>

#### **Relonchem Limited**

- For stock control enquiries please contact Relonchem Customer Service team on +44 (0) 151 422 1200 or sales@relonchem.com
- For medical information enquiries please contact Relonchem Pharmacovigilance Department on +44 (0) 151 556 1857 or medicalinformation@relonchem.com

### **Noumed Life Sciences Limited**

- For stock control enquiries please contact Noumed Life Sciences Limited Customer Service team on +44 (0) 2033998900 or <a href="mailto:nicole.mascowe@noumed.co.uk">nicole.mascowe@noumed.co.uk</a>
- For medical information enquiries please contact Noumed Life Sciences Limited
   Pharmacovigilance Department on Tel +44 (0) 2033998960 or <a href="mailto:akhtarhms@skayedzan.co.uk">akhtarhms@skayedzan.co.uk</a>

#### **Medreich PLC**

- For stock control enquiries please contact Medreich Plc. Customer Service team on +44 (0) 20 8831 1580 or cs\_team@medreich.co.uk
- For medical information enquiries please contact Medreich Plc. Pharmacovigilance Department on +44 (0) 20 8831 1580 or gagroup@medreich.co.uk

Recipients should bring it to the attention of relevant contacts by copy of this letter.

NHS Regional teams are asked to forward this to relevant clinics, general practitioners and community pharmacists.

EL (19)A/37 Page 3 of 4





Yours faithfully

Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574